Cortexyme, Inc.
269 E. Grand Avenue
South San Francisco
CA
94080
United States
Tel: 6508674547
Website: http://www.cortexyme.com/
Email: careers@cortexyme.com
83 articles with Cortexyme, Inc.
-
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
9/8/2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate, COR588.
-
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
9/7/2021
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
-
The Annual Biomarkers for Alzheimer’s Disease Summit is running from August 25-26. Here’s a look at some of the top stories from day one.
-
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
8/25/2021
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
-
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
8/18/2021
Cortexyme, Inc. will participate as a featured speaker covering its pivotal Phase 2/3 GAIN Trial
-
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
8/9/2021
Cortexyme, Inc. today provided an update on expected clinical top-line data and reported second quarter 2021 financial results.
-
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
8/4/2021
Cortexyme to Present at Canaccord Genuity' s 41 st Annual Growth Conference on August 11 th
-
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
7/26/2021
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
-
Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.
-
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
7/23/2021
Cortexyme, Inc. announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.
-
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
-
Cortexyme to Present New Data at AAIC 2021
7/22/2021
Cortexyme, Inc. announced that it will present two poster presentations at the Alzheimer's Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.
-
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
7/21/2021
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
-
Cortexyme to Host Symposium at AAIC 2021
7/19/2021
Cortexyme, Inc. announced that it will host a corporate sponsored symposium and dinner held in conjunction with the Alzheimer's Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.
-
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
7/8/2021
Part 1 to be held Friday July 23 at 10:00 a.m. ET: Innovation in Periodontal Disease – A Major Unmet Medical Need Part 2 to be held Friday July 30 at 10:00 a.m. ET: Innovation in Alzheimer's Disease – Getting to the Root Cause of Neurodegeneration
-
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
6/1/2021
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021
-
Cortexyme to Present at Investor Conferences in June 2021
5/26/2021
Cortexyme, Inc., a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer and chief financial officer, will participate at the following virtual investor conferences in June 2021
-
Cortexyme Provides Business Update and Reports First Quarter 2021 Results
5/10/2021
Top-line data from 643-subject Alzheimer’s disease pivotal GAIN Trial expected in fourth quarter 2021 Top-line data from 233-subject periodontal disease Phase 2 REPAIR sub-study of the GAIN Trial expected in fourth quarter 2021
-
Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021
5/4/2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will participate in a fireside chat at the BofA Securities 2021 Healthcare Conference, a virtual event
-
Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021
3/25/2021
Cortexyme to Present at the Stifel 3 rd Annual CNS Day on April 1, 2021